Press Room


    Press Release - January 17, 2001

    Pheromone Sciences Corp Announces Positive Clinical Trial Results

    Pheromone Sciences Corp (CDNX:PHS), today announced positive clinical trial results on its lead product, the PSC Fertility Monitor'. The trial was conducted with 21 normal healthy women at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial compared the efficacy of the PSC Fertility Monitor' to current techniques for detecting fertility and ovulation. Results confirmed that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date, while also providing women with up to four days advance notice of ovulation. This accuracy compares very favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

    In commenting on the outcome, Dr. Casper stated, "The results of this trial suggest that the PSC Fertility Monitor' represents a major advance in the field of fertility and ovulation prediction. The PSC Fertility Monitor' provides more advance notice than other available methods with reliable accuracy, in a convenient, non-invasive manner. This would also provide a new tool for couples engaged in family planning".

    The PSC Fertility Monitor' offers a new user- friendly option in family planning. This product, which is housed in a modern styled wristwatch like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility Monitor' is a proprietary, non-invasive device which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor enabling it to take up to 12 daily measurements from the skin surface and to evaluate the data in order to predict the status of the user as being not-fertile, fertile or ovulating. Results can be viewed at any time on the LCD screen of the device or as a computer- generated graphical printout for medical professionals.

    "This is another significant milestone successfully achieved," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "We remain committed to our goal of completing U.S. regulatory submissions and concluding a strategic alliance for the marketing and distribution rights for this product come year end."

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    443 King Street East Toronto, Ont, Canada M5A 1L5 tel: (416) 861-9854 fax: (416) 861-9950

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095

    Nick Borrelly (604) 872-2012


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News